AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 million to license the rights to these preclinical and clinical-stage compounds that address muscarinic receptors to potentially treat a range of neurological disorders.
